Skip to main content

Advertisement

SpringerLink
Log in

Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Primary chemotherapy achieves high clinical response rates and facilitates breast conservation in many patients with large and locally advanced breast cancer. It may also serve to indicate responsiveness to chemotherapeutic agents. A pathological complete response to primary chemotherapy is a primary predictor and surrogate marker of long-term outcome, but occurs in only approximately 15% of patients. Docetaxel is of particular interest in this setting. Primary docetaxel chemotherapy has single-agent activity in both dose-dense and traditional schedules, with acceptable tolerability. Furthermore, concomitant docetaxel–anthracycline schedules have shown promise in Phase II trials, achieving clinical overall response rates (ORRs) of 77–96%, pathological complete responses of up to 24%, and breast conservation in up to 89% of patients.

Two Phase III studies have shown that pathological complete response is significantly improved with the addition of docetaxel to anthracycline-based therapy versus the latter alone: the Aberdeen study achieved a rate of 34% versus 16%, respectively (p = 0.04), and the NSABP-B27 study a rate of 26% versus 14%, respectively (p < 0.001). The Aberdeen study has suggested that the addition of docetaxel may yield a survival benefit at 5 years (p = 0.04). The Phase II GEPAR-DUO study hints at a benefit for sequential over concomitant docetaxel-based therapy, with improvements in both clinical response (ORR 87% versus 77%, respectively) and pathological complete response (23% versus 12%, respectively). Non-anthracycline docetaxel-based primary regimens have shown early promise. As we continue to define the optimal regimen, a growing body of evidence supports the use of docetaxel in primary chemotherapeutic regimens for breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. AP Forrest PA Levack U Chetty RA Hawkins WR Miller JF Smyth TJ Anderson (1986) ArticleTitleA human tumour model Lancet 2 840–842 Occurrence Handle2876282 Occurrence Handle1:STN:280:BiiD3Mzmt1w%3D

    PubMed  CAS  Google Scholar 

  2. L Mauriac M Durand A Avril JM Dilhuydy (1991) ArticleTitleEffects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2 347–354 Occurrence Handle1:STN:280:By2D283mt1Y%3D Occurrence Handle1954179

    CAS  PubMed  Google Scholar 

  3. SD Heys JM Eremin TK Sarkar AW Hutcheon A Ah-See O Eremin (1994) ArticleTitleRole of multimodality therapy in the management of locally advanced carcinoma of the breast J Am Coll Surg 179 493–504 Occurrence Handle7921405 Occurrence Handle1:STN:280:ByqD3crmtFE%3D

    PubMed  CAS  Google Scholar 

  4. B Fisher J Bryant N Wolmark E Mamounas A Brown ER Fisher DL Wickerham M Begovic A DeCillis A Robidoux RG Margolese AB Cruz SuffixJr JL Hoehn AW Lees NV Dimitrov HD Bear (1998) ArticleTitleEffect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672–2685 Occurrence Handle1:CAS:528:DyaK1cXlsFCgurg%3D Occurrence Handle9704717

    CAS  PubMed  Google Scholar 

  5. IC Smith SD Heys AW Hutcheon ID Miller S Payne FJ Gilbert AK Ah-See O Eremin LG Walker TK Sarkar SP Eggleton KN Ogston (2002) ArticleTitleNeoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456–1466 Occurrence Handle10.1200/JCO.20.6.1456 Occurrence Handle1:CAS:528:DC%2BD38XivFeisbg%3D Occurrence Handle11896092

    Article  CAS  PubMed  Google Scholar 

  6. KN Ogston ID Miller S Payne AW Hutcheon TK Sarkar I Smith A Schofield SD Heys (2003) ArticleTitleA new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Breast 12 320–327 Occurrence Handle14659147

    PubMed  Google Scholar 

  7. AW Hutcheon SD Heys TK Sarkar KN Ogston O Eremin LG Walker ID Miller (2003) ArticleTitleDocetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. Breast Cancer Res Treat 82 (Suppl 1) S9

    Google Scholar 

  8. SD Heys AW Hutcheon TK Sarkar KN Ogston ID Miller S Payne I Smith LG Walker O Eremin (2002) ArticleTitleAberdeen Breast Group: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial Clin Breast Cancer 3 (Suppl. 2) S69–S74 Occurrence Handle10.3816/CBC.2002.s.015

    Article  Google Scholar 

  9. S Chan K Friedrichs D Noel T Pinter S Belle ParticleVan D Vorobiof R Duarte M Gil Gil I Bodrogi E Murray L Yelle G Minckwitz Particlevon S Korec P Simmonds F Buzzi R Gonzalez Mancha G Richardson E Walpole M Ronzoni M Murawsky M Alakl A Riva (1999) ArticleTitleProspective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer J Clin Oncol 17 2341–2354 Occurrence Handle10561296 Occurrence Handle1:CAS:528:DyaK1MXltlylt70%3D

    PubMed  CAS  Google Scholar 

  10. JM Nabholtz C Falkson D Campos J Szanto M Martin S Chan T Pienkowski J Zaluski T Pinter M Krzakowski D Vorobiof R Leonard I Kennedy N Azli M Murawsky A Riva P Pouillart (2003) ArticleTitleTAX 306 Study Group: docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial J Clin Oncol 21 968–975 Occurrence Handle12637459 Occurrence Handle1:CAS:528:DC%2BD2cXpsVGqs7g%3D

    PubMed  CAS  Google Scholar 

  11. PM Ravdin HA Burris Particle3 rd G Cook P Eisenberg M Kane WA Bierman J Mortimer E Genevois RE Bellet (1995) ArticleTitlePhase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer J Clin Oncol 13 2879–2885 Occurrence Handle8523050 Occurrence Handle1:CAS:528:DyaK28XmslOntw%3D%3D

    PubMed  CAS  Google Scholar 

  12. A Makris TJ Powles SE Ashley J Chang T Hickish VA Tidy AG Nash HT Ford (1998) ArticleTitleA reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer Ann Oncol 9 1179–1184 Occurrence Handle10.1023/A:1008400706949 Occurrence Handle1:STN:280:DyaK1M%2FnvFSnsg%3D%3D Occurrence Handle9862047

    Article  CAS  PubMed  Google Scholar 

  13. L Mauriac G MacGrogan A Avril M Durand A Floquet M Debled JM Dilhuydy F Bonichon (1999) ArticleTitleNeoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10 47–52 Occurrence Handle10.1023/A:1008337009350 Occurrence Handle1:STN:280:DyaK1M7ns1SitQ%3D%3D Occurrence Handle10076721

    Article  CAS  PubMed  Google Scholar 

  14. SM Scholl A Fourquet B Asselain JY Pierga JR Vilcoq JC Durand T Dorval T Palangie M Jouve P Beuzeboc P Pouillart (1994) ArticleTitleNeoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A 645–652 Occurrence Handle10.1016/0959-8049(94)90537-1 Occurrence Handle1:STN:280:ByuA287os1E%3D Occurrence Handle8080680

    Article  CAS  PubMed  Google Scholar 

  15. VF Semiglazov EE Topuzov JL Bavli VM Moiseyenko OA Ivanova IK Seleznev AA Orlov NY Barash OM Golubeva OF Chepic (1994) ArticleTitlePrimary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb–IIIa breast cancer Ann Oncol 5 591–595 Occurrence Handle1:STN:280:ByqD1crpvFI%3D Occurrence Handle7993833

    CAS  PubMed  Google Scholar 

  16. SM Scholl JY Pierga B Asselain P Beuzeboc T Dorval E Garcia-Giralt M Jouve T Palangie Y Remvikos JC Durand A Fourquet P Pouillart (1995) ArticleTitleBreast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A 1969–1975 Occurrence Handle8562150

    PubMed  Google Scholar 

  17. N Wolmark J Wang E Mamounas J Bryant B Fisher (2001) ArticleTitlePreoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96–102 Occurrence Handle11773300

    PubMed  Google Scholar 

  18. P Chollet S Amat H Cure M Latour Particlede G Bouedec ParticleLe MA Mouret-Reynier JP Ferriere JL Achard J Dauplat F Penault-Llorca (2002) ArticleTitlePrognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer Br J Cancer 86 1041–1046 Occurrence Handle10.1038/sj.bjc.6600210 Occurrence Handle1:STN:280:DC%2BD383hs1KgsA%3D%3D Occurrence Handle11953845

    Article  CAS  PubMed  Google Scholar 

  19. M Schelling N Avril J Nahrig W Kuhn W Romer D Sattler M Werner J Dose F Janicke H Graeff M Schwaiger (2000) ArticleTitlePositron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer J Clin Oncol 18 1689–1695 Occurrence Handle1:STN:280:DC%2BD3c3islyjsw%3D%3D Occurrence Handle10764429

    CAS  PubMed  Google Scholar 

  20. IC Smith AE Welch AW Hutcheon ID Miller S Payne F Chilcott S Waikar T Whitaker AK Ah-See O Eremin SD Heys FJ Gilbert PF Sharp (2000) ArticleTitlePositron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy J Clin Oncol 18 1676–1688 Occurrence Handle1:STN:280:DC%2BD3c3islyjsg%3D%3D Occurrence Handle10764428

    CAS  PubMed  Google Scholar 

  21. IC Smith ID Miller (2001) ArticleTitleIssues involved in research into the neoadjuvant treatment of breast cancer Anticancer Drugs 12 (Suppl. 1) S25–S29

    Google Scholar 

  22. J Chang TJ Powles DC Allred SE Ashley GM Clark A Makris L Assersohn RK Gregory CK Osborne M Dowsett (1999) ArticleTitleBiologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer J Clin Oncol 17 3058–3063 Occurrence Handle10506600 Occurrence Handle1:STN:280:DyaK1MvjvVWksg%3D%3D

    PubMed  CAS  Google Scholar 

  23. J Sjostrom C Blomqvist P Heikkila KV Boguslawski A Raisanen-Sokolowski NO Bengtsson I Mjaaland P Malmstrom B Ostenstadt J Bergh E Wist V Valvere E Saksela (2000) ArticleTitlePredictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer Clin Cancer Res 6 3103–3110 Occurrence Handle10955790 Occurrence Handle1:CAS:528:DC%2BD3cXmsVOmtr4%3D

    PubMed  CAS  Google Scholar 

  24. PA Ellis IE Smith K McCarthy S Detre J Salter M Dowsett (1997) ArticleTitlePreoperative chemotherapy induces apoptosis in early breast cancer Lancet 349 849 Occurrence Handle9121265 Occurrence Handle1:STN:280:ByiB3snos1I%3D

    PubMed  CAS  Google Scholar 

  25. B Fisher N Wolmark ER Fisher M Deutsch (1985) ArticleTitleLumpectomy and axillary dissection for breast cancer: surgical, pathological, and radiation considerations World J Surg 9 692–698 Occurrence Handle4060746 Occurrence Handle1:STN:280:BimD2cnivVc%3D

    PubMed  CAS  Google Scholar 

  26. MC Bissery D Guenard F Gueritte-Voegelstein F Lavelle (1991) ArticleTitleExperimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue Cancer Res 51 4845–4852 Occurrence Handle1680023 Occurrence Handle1:CAS:528:DyaK3MXmt1aqsbg%3D

    PubMed  CAS  Google Scholar 

  27. J Crown J M O’Leary (2000) ArticleTitleThe taxanes: an update Lancet 355 1176–1178 Occurrence Handle10.1016/S0140-6736(00)02074-2 Occurrence Handle1:CAS:528:DC%2BD3cXislegsrg%3D Occurrence Handle10791395

    Article  CAS  PubMed  Google Scholar 

  28. AP Launchbury N Habboubi (1993) ArticleTitleEpirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity Cancer Treat Rev 19 197–228 Occurrence Handle8334677 Occurrence Handle1:CAS:528:DyaK3sXlvFCqurs%3D

    PubMed  CAS  Google Scholar 

  29. R Bellot J Robert V Dieras JL Misset P Baille L Bozec L Vernillet A Riva N Azli P Pouillart (1998) ArticleTitleTaxotere® does not change the pharmacokinetic (PK) profile of doxorubicin (Dox) or doxorubicinol (Dx-ol) Proc Am Soc Clin Oncol 17 221a

    Google Scholar 

  30. S Amat P Bougnoux F Penault-Llorca F Fetissof H Cure F Kwiatkowski JL Achard G Body J Dauplat P Chollet (2003) ArticleTitlePrimary docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate Br J Cancer 88 1339–1345 Occurrence Handle10.1038/sj.bjc.6600916 Occurrence Handle1:CAS:528:DC%2BD3sXktFOgu7c%3D Occurrence Handle12778058

    Article  CAS  PubMed  Google Scholar 

  31. J Bines RG Martins PAO Carmo A Del Giglio A Vasconcelos A Cabral J Vinholes C Gusmao (2001) ArticleTitleInduction chemotherapy with weekly docetaxel (Taxotere®) in unfavourable locally advanced breast cancer (LABC) Eur J Cancer 37 6

    Google Scholar 

  32. L Estévez JM Cuevas A Anton J Florian JM Lopez-Vega A Velasco F Lobo A Herrero J Fortes (2003) ArticleTitleWeekly docetaxel (Taxotere®) is effective as primary chemotherapy for stage II and III breast cancer. Results of a phase II, multicenter study. Clin Cancer Res 9 686–692 Occurrence Handle12576436

    PubMed  Google Scholar 

  33. WJ Gradishar (1997) ArticleTitleDocetaxel as primary chemotherapy in patients with stage III breast cancer Oncology 11 (Suppl. 8) 15–18

    Google Scholar 

  34. B Chevallier H Roche JP Olivier P Chollet P Hurteloup (1993) ArticleTitleInflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 16 223–228 Occurrence Handle1:STN:280:ByyA3s3gtFY%3D Occurrence Handle8338056

    CAS  PubMed  Google Scholar 

  35. DM Sataloff BA Mason AJ Prestipino UL Seinige CP Lieber Z Baloch (1995) ArticleTitlePathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome J Am Coll Surg 180 297–306 Occurrence Handle7874340 Occurrence Handle1:STN:280:ByqC2sbjsFc%3D

    PubMed  CAS  Google Scholar 

  36. G Ganem M Tubiana-Hulin P Fumoleau M Combe JL Misset JM Vannetzel T Bachelot LR Ybarlucea ParticleDe V Lotz B Bendahmane V Dieras (2003) ArticleTitlePhase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer Ann Oncol 14 1623–1628 Occurrence Handle10.1093/annonc/mdg449 Occurrence Handle1:STN:280:DC%2BD3srgtlWqsw%3D%3D Occurrence Handle14581269

    Article  CAS  PubMed  Google Scholar 

  37. V Valero FJ Esteva AA Sahin DJ Booser EA Strom LT Esparza-Guerra MI Ross MF Rosales NK Ibrahim M Cirstofanil TA Buchholz KK Hunt GN Hortobagyi (2000) ArticleTitlePhase II trial of primary chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy +/- tamoxifen in locally advanced breast cancer Breast Cancer Res Treat 64 69

    Google Scholar 

  38. G Minckwitz Particlevon SD Costa W Eiermann JU Blohmer AH Tulusan C Jackisch M Kaufmann (1999) ArticleTitleMaximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel J Clin Oncol 17 1999–2005 Occurrence Handle10561250

    PubMed  Google Scholar 

  39. G Minckwitz Particlevon SD Costa G Raab JU Blohmer H Eidtmann J Hilfrich E Merkle C Jackisch G Gademann AH Tulusan W Eiermann E Graf M Kaufmann (2001) ArticleTitleGerman Preoperative Adriamycin-Docetaxel and German Adjuvant Breast Cancer Study Groups: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study J Clin Oncol 19 3506–3515

    Google Scholar 

  40. C Ferlini G Scambia M Distefano P Filippini G Isola A Riva E Bombardelli A Fattorossi P Benedetti Panici S Mancuso (1997) ArticleTitleSynergistic antiproliferative activity of tamoxifen and docetaxel on three estrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis Br J Cancer 75 884–891 Occurrence Handle9062411 Occurrence Handle1:CAS:528:DyaK2sXitlehsbk%3D

    PubMed  CAS  Google Scholar 

  41. A Matteis Particlede F Nuzzo G D’Aiuto V Labonia G Landi E Rossi AA Mastro G Botti E Maio ParticleDe F Perrone (2002) ArticleTitleDocetaxel plus epidoxorubicin as primary treatment in patients with large operable or locally advanced carcinoma of the breast. A single-center, phase II study. Cancer 94 895–901 Occurrence Handle10.1002/cncr.20335.abs Occurrence Handle11920456

    Article  PubMed  Google Scholar 

  42. C Wenzel GJ Locker M Schmidinger M Rudas S Taucher MF Gnant R Jakesz GG Steger (2002) ArticleTitleCombined analysis of two phase II trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel + granulocyte colony stimulating factor Anticancer Drugs 13 67–74 Occurrence Handle11914643 Occurrence Handle1:CAS:528:DC%2BD38XmvFCms70%3D

    PubMed  CAS  Google Scholar 

  43. L Luporsi L Vanlemmens B Coudert F Mayer J Bonneterre T Petit C Borel M Hirsch P Bey (2000) ArticleTitle6 cycles of FEC 100 versus 6 cycles of epirubicin–docetaxel (ED) as neoadjuvant chemotherapy in operable breast cancer patients (Pts): preliminary results of a randomized phase II trial of Girec S01 Proc Am Soc Clin Oncol 19 92

    Google Scholar 

  44. A Milla S Morales MA Burillo P Borrega I Machenes T Checa J Janariz JJ Illaramendi J Lizon (2001) ArticleTitleHigh-dose epirubicin plus docetaxel in locally advanced breast cancer (LABC). An ONCOPAZ and associated hospitals study. Breast Cancer Res Treat 69 271

    Google Scholar 

  45. C Wenzel GJ Locker U Pluschnig CC Zielinski M Rudas G Oberhuber MF Gnant S Taucher R Jakesz GG Steger (2002) ArticleTitlePhase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer Cancer Chemother Pharmacol 50 155–159 Occurrence Handle10.1007/s00280-002-0476-9 Occurrence Handle1:CAS:528:DC%2BD38Xls12ns7w%3D Occurrence Handle12172982

    Article  CAS  PubMed  Google Scholar 

  46. KD Miller W McCaskill-Stevens J Sisk DM Loesch F Monaco R Seshadri GW Sledge SuffixJr (1999) ArticleTitleCombination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group J Clin Oncol 17 3033–3037 Occurrence Handle1:CAS:528:DyaK1MXmslGmt7k%3D Occurrence Handle10506597

    CAS  PubMed  Google Scholar 

  47. G Minckwitz Particlevon G Raab M Schuette J Hilfrich JU Blohmer B Gerber SD Costa E Merkle H Eidtmann W Lampe C Jackisch A duBois A Caputo M Kaufmann SuffixJr (2002) ArticleTitleDose-dense versus sequential adriamycin/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2–3, N0–2 , M0)–primary endpoint analysis of the GEPAR-DUO Study Proc Am Soc Clin Oncol 21 43a

    Google Scholar 

  48. HD Bear S Anderson A Brown R Smith EP Mamounas B Fisher R Margolese H Theoret A Soran DL Wickerham N Wolmark (2003) ArticleTitleNational Surgical Adjuvant Breast and Bowel Project Protocol B-27: the effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-27 J Clin Oncol 21 4165–4174 Occurrence Handle10.1200/JCO.2003.12.005 Occurrence Handle14559892 Occurrence Handle1:CAS:528:DC%2BD2cXpsVajtrg%3D

    Article  PubMed  CAS  Google Scholar 

  49. C Jackisch G Minckwitz Particlevon H Eidtmann SD Costa G Raab JU Blohmer M Schutte B Gerber E Merkle G Gademann D Lampe J Hilfrich AH Tulusan A Caputo M Kaufmann (2002) ArticleTitleDose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: second interim analysis Clin Breast Cancer 3 276–280 Occurrence Handle12425756 Occurrence Handle1:CAS:528:DC%2BD38XpsVygt78%3D Occurrence Handle10.3816/CBC.2002.n.031

    Article  PubMed  CAS  Google Scholar 

  50. AW Hutcheon KN Ogston SD Heys IC Smith T Whitaker ID Miller S Payne A Ah-See O Eremin P Eggleton (2000) ArticleTitleThe Aberdeen Breast Group: primary chemotherapy in the treatment of breast cancer: significantly enhanced clinical and pathological response with docetaxel Proc Am Soc Clin Oncol 19 83a

    Google Scholar 

  51. J Hurley P Doliny C Gomez L Raez J Boggs S Franco Y Lee (2000) ArticleTitleHigh complete pathologic response rate of locally advanced breast cancers (LABC) to neoadjuvant (NEO) docetaxel and cisplatin chemotherapy Proc Am Soc Clin Oncol 19 127

    Google Scholar 

  52. JE Hurley P Doliny P Velez U Guatam I Reis O Silva C Gomez-Fernandez Y Lee SX Franco (2001) ArticleTitleHigh rate of axillary node clearance with neoadjuvant Herceptin, Taxotere, and cisplatin in locally advanced and inflammatory breast cancer Breast Cancer Res Treat 69 300

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Surgery, and Clinical and Medical Oncology, University of Aberdeen, Aberdeen, UK

    Steven D. Heys, Tarun Sarkar & Andrew W. Hutcheon

  2. Department of Surgery, University Medical Buildings, Foresterhill, Aberdeen, AB 9 2ZD, UK

    Steven D. Heys

Authors
  1. Steven D. Heys
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tarun Sarkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrew W. Hutcheon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven D. Heys.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heys, S.D., Sarkar, T. & Hutcheon, A.W. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival. Breast Cancer Res Treat 90, 169–185 (2005). https://doi.org/10.1007/s10549-004-1001-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-004-1001-0

Keywords

Search

Navigation